Table 6.
Association between Asian-specific PRSs and overall breast cancer risk.
| PRS | SNP selection | Number of SNPs published | Number of SNPs used in analyses | SD controls | OR per SD (95% CI) | AUC |
|---|---|---|---|---|---|---|
| Low et al.27 | Identified in Asian | 5 | 5 | 0.292 | 1.25 (1.23–1.27) | 0.563 |
| Lee et al.26 | Identified in European/Asian | 51 | 51 | 0.469 | 1.28 (1.26–1.30) | 0.562 |
| Wen et al.15 | Identified in European/Asian | 44 | 44 | 0.400 | 1.41 (1.39–1.44) | 0.586 |
| Hsieh et al.17 | Identified in European/Asian | 6 | 6 | 0.356 | 1.10 (1.08–1.11) | 0.533 |
| Chan et al.19 | Identified in European/Asian | 46 | 45a | 0.983 | 1.21 (1.19–1.23) | 0.558 |
| Mavaddat et al.7 | Identified in European | 313 | 287 | 0.564b | 1.51 (1.22–1.86)b | 0.617b |
PRSs were constructed using per allele log odds ratios as reported in the literature. As Asian case–control studies genotyped by iCOGs array and 744 samples from MYBRCA batch 1 were used as part of the development studies in Wen et al. (2016), to avoid upward bias, we restricted these evaluation analyses to Asian cases–controls studies genotyped using the OncoArray and removed overlapping samples in MYBRCA batch 1.
aOne SNP rs146699004 was not imputed and hence not included in the analyses.
bAnalyses of 287-SNP PRS was repeated using the same dataset as described.